Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Other financing activities: 2017-2025

Historic Other financing activities for Protagonist Therapeutics (PTGX) over the last 8 years, with Sep 2025 value amounting to $5.7 million.

  • Protagonist Therapeutics' Other financing activities fell 53.04% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.5 million, marking a year-over-year increase of 6.96%. This contributed to the annual value of $26.5 million for FY2024, which is 454.11% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Other financing activities stood at $5.7 million for Q3 2025, which was up 93.47% from $2.9 million recorded in Q2 2025.
  • Protagonist Therapeutics' Other financing activities' 5-year high stood at $12.1 million during Q3 2024, with a 5-year trough of -$2.3 million in Q1 2023.
  • Its 3-year average for Other financing activities is $4.3 million, with a median of $2.9 million in 2025.
  • As far as peak fluctuations go, Protagonist Therapeutics' Other financing activities crashed by 188.39% in 2023, and later skyrocketed by 1,080.31% in 2024.
  • Quarterly analysis of 5 years shows Protagonist Therapeutics' Other financing activities stood at $2.3 million in 2021, then slumped by 76.36% to $553,000 in 2022, then dropped by 6.15% to $519,000 in 2023, then surged by 676.69% to $4.0 million in 2024, then slumped by 53.04% to $5.7 million in 2025.
  • Its Other financing activities was $5.7 million in Q3 2025, compared to $2.9 million in Q2 2025 and $11.9 million in Q1 2025.